Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial [version 1; referees: 3 approved]

Background: By the early 1980s, tuberculosis treatment was shortened from 24 to 6 months, maintaining relapse rates of 1-2%. Subsequent trials attempting shorter durations have failed, with 4-month arms consistently having relapse rates of 15-20%. One trial shortened treatment only among those witho...

Full description

Bibliographic Details
Main Authors:	Ray Y. Chen, Laura E. Via, Lori E. Dodd, Gerhard Walzl, Stephanus T. Malherbe, André G. Loxton, Rodney Dawson, Robert J. Wilkinson, Friedrich Thienemann, Michele Tameris, Mark Hatherill, Andreas H. Diacon, Xin Liu, Jin Xing, Xiaowei Jin, Zhenya Ma, Shouguo Pan, Guolong Zhang, Qian Gao, Qi Jiang, Hong Zhu, Lili Liang, Hongfei Duan, Taeksun Song, David Alland, Michael Tartakovsky, Alex Rosenthal, Christopher Whalen, Michael Duvenhage, Ying Cai, Lisa C. Goldfeder, Kriti Arora, Bronwyn Smith, Jill Winter, Clifton E. Barry III, Predict TB Study Group
Format:	Article
Language:	English
Published:	F1000 Research Ltd 2017-11-01
Series:	Gates Open Research
Subjects:	Antimicrobials & Drug Resistance Bacterial Infections Immunological Biomarkers
Online Access:	https://gatesopenresearch.org/articles/1-9/v1

Internet

https://gatesopenresearch.org/articles/1-9/v1

Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial [version 1; referees: 3 approved]

Internet

Similar Items